<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJEpi</journal-id><journal-title-group><journal-title>Open Journal of Epidemiology</journal-title></journal-title-group><issn pub-type="epub">2165-7459</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojepi.2021.111006</article-id><article-id pub-id-type="publisher-id">OJEpi-107039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiological Characteristics of COVID-19 Confirmed Cases in Muscat Governorate, Sultanate of Oman
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lamya</surname><given-names>Al Balushi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatma</surname><given-names>Al Fahdi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Thamra</surname><given-names>Al Ghafri</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammed</surname><given-names>Amin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jeffrey</surname><given-names>Singh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Balqees</surname><given-names>Al Siyabi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariam</surname><given-names>Al Kalbani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maya</surname><given-names>Al Kindi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatma</surname><given-names>Al Balushi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Haleema</surname><given-names>Al Ghazaili</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Malak</surname><given-names>Al Alwai</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Salwa</surname><given-names>Al Mashari</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hanan</surname><given-names>Al Kindi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ahlam</surname><given-names>Al Rumhi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibtisam</surname><given-names>Al Shidhani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zainb</surname><given-names>Al Balushi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Padmamohan</surname><given-names>J. Kurup</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatma</surname><given-names>Al Ajmi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Primary Health Care, Directorate General for Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman</addr-line></aff><aff id="aff5"><addr-line>Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman</addr-line></aff><aff id="aff1"><addr-line>Disease Surveillance and Control, Directorate General for Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman</addr-line></aff><aff id="aff4"><addr-line>Directorate General of Khoula Hospital, Muscat, Oman</addr-line></aff><aff id="aff2"><addr-line>Directorate General for Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>12</month><year>2020</year></pub-date><volume>11</volume><issue>01</issue><fpage>56</fpage><lpage>69</lpage><history><date date-type="received"><day>6,</day>	<month>December</month>	<year>2020</year></date><date date-type="rev-recd"><day>1,</day>	<month>February</month>	<year>2021</year>	</date><date date-type="accepted"><day>4,</day>	<month>February</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: The coronavirus disease 2019 (COVID-19) was declared as pandemic by WHO by March 11th. First case reported in Oman was on 24th February 2020 and later the country went through stages of epidemic progression. This study describes the sociodemographic and epidemiological characteristics of confirmed COVID-19 cases in Muscat governorate and related outcomes. 
  Materials and Methods: This is a descriptive, exploratory analysis of all lab confirmed COVID 19 cases that were reported from 1st February to 31st May 2020. Data for the study was primarily extracted from notifications system established for surveillance (Tarassud). Secondary data sources were, contact listings and hospital medical records.
   Results: 11,648 initial cases of confirmed COVID-19 infections were included. The mean age was 35 years, 84.7% (N = 9862) were males, 25.9% (N = 3017) were Omanis, and 74.1% (N = 8631) were expatriates of which Indian origin were the majority (37%). Fever and cough were the most common presentations (46.3% and 29.5% respectively). Diabetes and hypertension were the most common comorbidities (4.9% and 4.6% respectively). Hospital admission was required for 7% (N = 811) of the total reported cases, out of them 171 cases (21%) were admitted to ICU, where 107 (13.2%) were ventilated. The case fatality rate (CFR) was 0.9%. 158 clusters containing 2949 contacts were identified from case records and categorised into 3 groups based on their exposure settings. The incubation period measured was 8 days (IQR 4.0 - 15.0) for workplace, 8 days (IQR 4 - 17) for dormitory and 4 days (IQR 2.0 - 7.0) for family groups. The secondary attack rate (SAR) estimated was 41.6% (95% CI: 0.34 - 0.48), 52% (95% CI: 0.40 - 0.63) and 33% (95% CI: 0.27 - 0.38) for workplace, dormitory and family groups, respectively. 
  Conclusion: Results of this study, determine the transmission trend of COVID-19 in a country with high immigrant population. These findings could be utilised for further response planning in similar settings.
 
</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd> Epidemiological Characteristics</kwd><kwd> Infectious Disease</kwd><kwd> Cluster</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The current pandemic of coronavirus disease 2019 (COVID-19) began in Wuhan city last December 2019 and spread rapidly throughout China and the world [<xref ref-type="bibr" rid="scirp.107039-ref1">1</xref>]. WHO declared the disease a public health emergency of international concern (PHEIC) on 30 January 2020, and a pandemic on 11 March 2020 [<xref ref-type="bibr" rid="scirp.107039-ref2">2</xref>]. COVID-19 is caused by SARA-CoV2, a single-stranded enveloped RNA virus belong to the genus betacorona [<xref ref-type="bibr" rid="scirp.107039-ref3">3</xref>].</p><p>As of May 31st, 2020, the disease affected almost 6 million people and caused 367,166 deaths globally [<xref ref-type="bibr" rid="scirp.107039-ref4">4</xref>]. SARA-CoV2 could cause clusters of severe infection similar to that of SARS-CoV [<xref ref-type="bibr" rid="scirp.107039-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref6">6</xref>]. The clinical presentation ranges from being asymptomatic to severe infections. Around 80% of the infected cases have mild symptoms [<xref ref-type="bibr" rid="scirp.107039-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref7">7</xref>]. However, 7% - 12% of individuals progress into severe illness requiring critical care management that includes ICU admissions and mechanical ventilation [<xref ref-type="bibr" rid="scirp.107039-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref9">9</xref>].</p><p>Mortality from the disease is more prevalent in the elderly and those with underlying pre-existing conditions [<xref ref-type="bibr" rid="scirp.107039-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref9">9</xref>].</p><p>On 24th February 2020, Department of Disease Surveillance and Control (DSC), Muscat Governorate, received notification from the reference Central Public Health Laboratory (CPHL) confirming COVID-19 in two travellers who returned from the Islamic Republic of Iran. By 26th March, the total number surged over 100 [<xref ref-type="bibr" rid="scirp.107039-ref10">10</xref>], and local transmission of the disease was evident. The first death was reported on 31st March 2020. The patient was a 72-year-old citizen [<xref ref-type="bibr" rid="scirp.107039-ref11">11</xref>], who worked as a seller in a traditional Market which is attended by many tourists.</p><p>Based on the alert issued from WHO, several prompt interventions were undertaken by the Ministry of Health as preparedness for COVID-19 pandemic. These include initiation of surveillance at point of entry for travellers coming from the affected countries and quarantining them for 14 days, increasing the capacity of the CPHL for testing suspect cases, distribution of testing guidelines, infection prevention and control protocols, algorithms for suspected case definition and testing was issued and distributed to all relevant health institutions. Health promotion activities targeting the community were also commenced that promoted hand hygiene, avoiding public gathering and social distancing.</p><p>Laboratory confirmation of SARS-CoV-2 was performed at the CPHL, and subsequently in certified tertiary care hospitals. RT-PCR assays were performed in accordance with the protocol established by the WHO [<xref ref-type="bibr" rid="scirp.107039-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref14">14</xref>].</p><p>Suspect case definitions were periodically reviewed to adapt local epidemiology and developments in diagnostic testing for COVID-19. However, a definition for a confirmed case remained unchanged as a case tested positive by RT-PCR test.</p><p>The current study aims to describe the sociodemographic and epidemiological characteristics of confirmed COVID-19 cases in Muscat governorate and the related outcomes.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Setting</title><p>Muscat Governorate is the capital of the Sultanate of Oman. The 2018 mid-year population of the Country was 4,601,706. Muscat has the highest population density with a population of 1.4 million, of which 64% are expatriate population [<xref ref-type="bibr" rid="scirp.107039-ref15">15</xref>], where significant proportion are workers who lived in a dormitory setting. The major point of entry to Oman is the Muscat International Airport which caters to around 15 million passengers per year [<xref ref-type="bibr" rid="scirp.107039-ref16">16</xref>]. Thus, the threat of the importation of the disease was highest in Muscat.</p></sec><sec id="s2_2"><title>2.2. Methods</title><p>This is a descriptive, exploratory analysis of all lab-confirmed COVID 19 cases that were reported from 1st February to 31st May 2020. Data for the study was extracted primarily from the Ministry of Health electronic notifications system “Tarassud” and paper notifications from few institutions that had limited access to “Tarassud”. The electronic and paper notification forms contain information about the patients’ Sociodemography, in addition to disease signs and symptoms, symptom onset date, risk factors, comorbidities, source of infection and disease outcome. Admission date, discharge date, ventilation use and the outcome data of the admitted patients were extracted from hospital records. All SARS-CoV2 confirmed cases diagnosed from February 2020 until the end of May 2020 in Muscat Governorate were included in the study.</p></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>Data were entered into a spreadsheet and analysed using Statistical Package for Social Sciences (SPSS) for Windows, version 20.0 software (SPSS Inc., Illinois, USA). The epidemic curve was constructed and interpreted, in addition to the descriptive statistics of clusters and exposure. Numbers and percentages were used to describe sociodemographic characteristics and age groups, in addition to disease symptoms, comorbidities and risk factors. Mean (&#177;standard deviation. SD) were used to describe age, duration of illness and length of hospital admission. Independent t-test was used for comparison of means, chi-square tests for comparison of proportions. For all tests, p-value ≤ 0.05 was considered significant. Bivariate analysis associated with admissions (severity) and among admitted, using multi-linear regression model attempted to identify factors that led to increased duration of admission.</p></sec><sec id="s2_4"><title>2.4. Ethical Approval</title><p>Ethical approval was obtained through the ethical committee of Muscat governorate, Directorate General of Planning and Studies at the Ministry of Health. Anonymous data already available at the established notification process for COVID-19 were collected.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Social and Demography</title><p>The total number of samples taken for SARS CoV-2 testing from February 2020 until the end of May 2020 was 37,615 samples, out of which 11,648 (30.9%) have been tested positive for COVID-19. The mean age of confirmed cases was 35 years (&#177;12.9 SD) and ranged from 3 months to 94 years (<xref ref-type="table" rid="table1">Table 1</xref>). Out of the total cases, 84.7% (N = 9862) were males and 15.3% (N = 1786) were females. Of the total cases, Omanis constituted 25.9% (N = 3017), while 74.1% (N = 8631) were expatriates. The proportions of the major affected foreign nationalities were Indian (37%), Bangladeshi (23.3%) and Pakistani (6.1%). Age group from 21 to 40 years was the most affected group (N = 7343, 63%).</p><p>As shown in (<xref ref-type="fig" rid="fig1">Figure 1</xref>), cases started to increase gradually in early May to reach a surge by the end of the month to exceed 500 cases daily. The first reported death from disease was on 31st March 2020 and by the end of May, the total fatalities reached 103 cases, out of them 88 (85.4%) were males and 31 (30.1%) were Omanis. The case fatality rate (CFR) was 0.9%. As of 31st May, 8435 cases (72.4%) have recovered and 3110 (26.7%) remain active. <xref ref-type="fig" rid="fig2">Figure 2</xref> compares incidence rates per 100,000 between Omanis and expatriates. As shown in the figure, at the initial phase, the number of infected expatriates outnumbered Omanis. Later, the diseases affected the Omani population in nearly similar rates.</p></sec><sec id="s3_2"><title>3.2. Clinical Presentation</title><p>Clinical presentations of most cases were mild to moderate, with 6.9% (N = 808) asymptomatic. Fever and cough were the most common presentations (46.3% and 29.5% respectively). 15.6% of cases had one or more associated comorbidities or risk factors. Diabetes and hypertension were the most common co-morbidities (4.9% and 4.6% respectively) and smoking was the most common risk factor (4.6%) (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demography of COVID-19 reported cases in Muscat</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Omani N (%)</th><th align="center" valign="middle" >Non-Omani N (%)</th><th align="center" valign="middle" >Total N (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="4"  >Gender</td></tr><tr><td align="center" valign="middle" >Males</td><td align="center" valign="middle" >1766 (15.2)</td><td align="center" valign="middle" >8096 (69.5)</td><td align="center" valign="middle" >9862 (84.7)</td></tr><tr><td align="center" valign="middle" >Females</td><td align="center" valign="middle" >1251 (10.7)</td><td align="center" valign="middle" >535 (4.6)</td><td align="center" valign="middle" >1786 (15.3)</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Age groups</td></tr><tr><td align="center" valign="middle" >0 - 20 Years</td><td align="center" valign="middle" >614 (5.3)</td><td align="center" valign="middle" >334 (2.9)</td><td align="center" valign="middle" >948 (8.1)</td></tr><tr><td align="center" valign="middle" >21 - 40 Years</td><td align="center" valign="middle" >1605 (13.8)</td><td align="center" valign="middle" >5738 (49.3)</td><td align="center" valign="middle" >7343 (63.0)</td></tr><tr><td align="center" valign="middle" >41 - 60 Years</td><td align="center" valign="middle" >604 (5.2)</td><td align="center" valign="middle" >2378 (20.4)</td><td align="center" valign="middle" >2982 (25.7)</td></tr><tr><td align="center" valign="middle" >Above 60 Years</td><td align="center" valign="middle" >194 (1.7)</td><td align="center" valign="middle" >181 (1.6)</td><td align="center" valign="middle" >375 (3.2)</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Residence</td></tr><tr><td align="center" valign="middle" >Mutrah</td><td align="center" valign="middle" >502 (4.3)</td><td align="center" valign="middle" >3786 (32.5)</td><td align="center" valign="middle" >4288 (36.8)</td></tr><tr><td align="center" valign="middle" >Seeb</td><td align="center" valign="middle" >1514 (13.0)</td><td align="center" valign="middle" >2140 (18.4)</td><td align="center" valign="middle" >3654 (31.4)</td></tr><tr><td align="center" valign="middle" >Bowshar</td><td align="center" valign="middle" >396 (3.4)</td><td align="center" valign="middle" >2288 (19.6)</td><td align="center" valign="middle" >2684 (23.0)</td></tr><tr><td align="center" valign="middle" >Muscat</td><td align="center" valign="middle" >86 (0.7)</td><td align="center" valign="middle" >299 (2.6)</td><td align="center" valign="middle" >385 (3.3)</td></tr><tr><td align="center" valign="middle" >Amerat</td><td align="center" valign="middle" >409 (3.5)</td><td align="center" valign="middle" >52 (0.4)</td><td align="center" valign="middle" >461 (4.0)</td></tr><tr><td align="center" valign="middle" >Quriyat</td><td align="center" valign="middle" >59 (0.5)</td><td align="center" valign="middle" >5 (0.04)</td><td align="center" valign="middle" >64 (0.5)</td></tr><tr><td align="center" valign="middle" >Other regions</td><td align="center" valign="middle" >51 (0.4)</td><td align="center" valign="middle" >61 (0.5)</td><td align="center" valign="middle" >112 (1.0)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Factors associated with disease severity</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Total N (%)</th><th align="center" valign="middle" >Not admitted N (%)</th><th align="center" valign="middle" >Admitted N (%)</th><th align="center" valign="middle" >p values</th></tr></thead><tr><td align="center" valign="middle"  colspan="5"  >Age groups</td></tr><tr><td align="center" valign="middle" >0 - 20 Years</td><td align="center" valign="middle" >948 (8.1)</td><td align="center" valign="middle" >934 (98.5)</td><td align="center" valign="middle" >14 (1.5)</td><td align="center" valign="middle"  rowspan="4"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >21 - 40 Years</td><td align="center" valign="middle" >7343 (63.0)</td><td align="center" valign="middle" >7000 (95.3)</td><td align="center" valign="middle" >343 (4.7)</td></tr><tr><td align="center" valign="middle" >41 - 60 Years</td><td align="center" valign="middle" >2982 (25.6)</td><td align="center" valign="middle" >2666 (89.4)</td><td align="center" valign="middle" >316 (10.6)</td></tr><tr><td align="center" valign="middle" >&gt;60 Years</td><td align="center" valign="middle" >375 (3.2)</td><td align="center" valign="middle" >237 (63.2)</td><td align="center" valign="middle" >138 (36.8)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Gender</td></tr><tr><td align="center" valign="middle" >Males</td><td align="center" valign="middle" >9862 (84.7)</td><td align="center" valign="middle" >9203 (93.3)</td><td align="center" valign="middle" >659 (6.7)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Females</td><td align="center" valign="middle" >1786 (15.3)</td><td align="center" valign="middle" >1634 (91.5)</td><td align="center" valign="middle" >152 (8.5)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Nationality</td></tr><tr><td align="center" valign="middle" >Omani</td><td align="center" valign="middle" >3017 (25.9)</td><td align="center" valign="middle" >2749 (91.1)</td><td align="center" valign="middle" >268 (8.9)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Expatriates</td><td align="center" valign="middle" >8631 (74.1)</td><td align="center" valign="middle" >8088 (93.7)</td><td align="center" valign="middle" >543 (6.3)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Symptoms*</td></tr><tr><td align="center" valign="middle" >Fever present</td><td align="center" valign="middle" >5394 (46.3)</td><td align="center" valign="middle" >4903 (90.9)</td><td align="center" valign="middle" >491 (9.1)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Fever absent</td><td align="center" valign="middle" >6254 (53.7)</td><td align="center" valign="middle" >5934 (94.9)</td><td align="center" valign="middle" >320 (5.1)</td></tr><tr><td align="center" valign="middle" >Cough present</td><td align="center" valign="middle" >3438 (29.5)</td><td align="center" valign="middle" >3064 (89.1)</td><td align="center" valign="middle" >374 (10.9)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Cough absent</td><td align="center" valign="middle" >8210 (70.5)</td><td align="center" valign="middle" >7773 (94.7)</td><td align="center" valign="middle" >437 (5.3)</td></tr><tr><td align="center" valign="middle" >Breathlessness</td><td align="center" valign="middle" >507 (4.4)</td><td align="center" valign="middle" >317 (62.5)</td><td align="center" valign="middle" >190 (37.5)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >No Breathlessness</td><td align="center" valign="middle" >11,141 (95.6)</td><td align="center" valign="middle" >10,520 (94.4)</td><td align="center" valign="middle" >621 (5.6)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Comorbidities</td></tr><tr><td align="center" valign="middle" >Diabetes-Yes</td><td align="center" valign="middle" >572 (4.9)</td><td align="center" valign="middle" >407 (71.2)</td><td align="center" valign="middle" >165 (28.8)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Diabetes-No</td><td align="center" valign="middle" >11,076 (95.1)</td><td align="center" valign="middle" >10,430 (94.2)</td><td align="center" valign="middle" >646 (5.8)</td></tr><tr><td align="center" valign="middle" >Hypertension-Yes</td><td align="center" valign="middle" >534 (4.6)</td><td align="center" valign="middle" >373 (69.9)</td><td align="center" valign="middle" >161 (30.1)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Hypertension-No</td><td align="center" valign="middle" >11,114 (95.4)</td><td align="center" valign="middle" >10,464 (94.2)</td><td align="center" valign="middle" >650 (5.8)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Risk factors**</td></tr><tr><td align="center" valign="middle" >Smoking-Yes</td><td align="center" valign="middle" >530 (4.6)</td><td align="center" valign="middle" >492 (92.8)</td><td align="center" valign="middle" >38 (7.2)</td><td align="center" valign="middle"  rowspan="2"  >0.84</td></tr><tr><td align="center" valign="middle" >Smoking-No</td><td align="center" valign="middle" >11,118 (95.4)</td><td align="center" valign="middle" >10,345 (93.0)</td><td align="center" valign="middle" >773 (7.0)</td></tr><tr><td align="center" valign="middle" >Alcohol use-Yes</td><td align="center" valign="middle" >88 (0.8)</td><td align="center" valign="middle" >77 (87.5)</td><td align="center" valign="middle" >11 (12.5)</td><td align="center" valign="middle"  rowspan="2"  >0.04</td></tr><tr><td align="center" valign="middle" >Alcohol use-No</td><td align="center" valign="middle" >11,560 (99.2)</td><td align="center" valign="middle" >10,760 (93.1)</td><td align="center" valign="middle" >800 (6.9)</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >84 (0.7)</td><td align="center" valign="middle" >60 (71.4)</td><td align="center" valign="middle" >24 (28.6)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >No Obesity</td><td align="center" valign="middle" >11,564 (99.3)</td><td align="center" valign="middle" >10,777 (93.2)</td><td align="center" valign="middle" >787 (6.8)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Duration of illness (Median &amp; Inter quartile range)</td></tr><tr><td align="center" valign="middle" >Omani</td><td align="center" valign="middle" >5 (IQR 3 - 8)</td><td align="center" valign="middle" >5 (IQR 3 - 8)</td><td align="center" valign="middle" >11 (IQR 6 - 20)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Expatriates</td><td align="center" valign="middle" >3 (IQR 1 - 6)</td><td align="center" valign="middle" >3 (IQR 1 - 6)</td><td align="center" valign="middle" >6 (IQR 2 - 10)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>*Other symptoms included Myalgia (N = 1376, 11.8%), Abdominal pain, Nausea and vomiting (N = 97, 0.8%), Chest pain (N = 37, 0.3%), Dizziness (N = 21, 0.3%) and 4 patients presented with GI bleeding.</p></sec><sec id="s3_3"><title>3.3. Admission and Disease Severity</title><p>The hospitalisation was taken as an index of severity for this study (<xref ref-type="table" rid="table2">Table 2</xref>). Hospital admission was required for 7% (N = 811) of the total reported cases, 171 cases (21%) were admitted to ICU and 107 (13.2%) were ventilated. Males represented 81.3% (N = 659) of the total admitted cases, however, the rate of hospital admission among females was relatively higher than among males (8.5% vs. 6.7% respectively, x2 (1) = 7.80, p &lt; 0.01) and also among Omanis than Expatriates (8.9% vs. 6.3% respectively, x2 (1) = 23.18, p &lt; 0.01). Older age groups tend to have more admission rates than younger age groups (x2 for trend (1) = 478.12, p &lt; 0.001). There was no significant difference in the rates of admission among smokers than non-smokers (p = 0.84). This finding was consistent even after adjustment for gender. Admission rates were higher among alcoholic (x2 (1) = 4.2, p = 0.04) and obese individuals (x2 (1) = 61, p &lt; 0.01).</p><p>There was no significant difference between mean days of admission neither by gender (531) = 1.69, p = 0.09) nor by nationality (t (531) = 0.62, p = 0.54).</p><p>With regards to rates of “ventilator use” there were no significant gender differences (x2 (1) = 0.14, p = 0.71) or nationality differences (x2 (1) = 0.90, p = 0.34). The rates of ventilation tend to increase with age groups (x2 for trend = 156.65, p &lt; 0.01). Ventilation was also associated with obesity (x2 (1) = 166.10, p &lt; 0.01), Diabetes (x2 (1) = 352.02, p &lt; 0.01) and hypertension (x2 (1) = 382.01, p &lt; 0.01). Ventilation was not associated with alcohol (x2 (1) = 1.8, p = 0.18), nor with smoking (x2 (1) = 1.31, p = 0.25).</p><p>A multiple linear regression model was applied to identify factors that predict the duration of hospital stay in days such as patient age, gender, and associated co-morbidities. Age, Diabetic status, Obesity and Hypertension were found to be significant predictors after adjusting for other independent variables (<xref ref-type="table" rid="table3">Table 3</xref>). Patients’ duration of admission increased 2.2 days in diabetics, 5.4 days in obese, and by one day per year of age.</p><p>Concerning epidemic progression, three-day moving average was used to calculate doubling time. Doubling time peaked around April 25 and declined to remain consistent between 10 to 16 days (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Initially, cases were travel-associated with a gradual shift to dormitory and family clusters and after 6 weeks from initial case report community transmission was established.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Factors associated with longer duration of hospital stay</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Independent variables</th><th align="center" valign="middle"  colspan="3"  >Un-standardized Coefficients (B) with 95% Confidence Interval</th><th align="center" valign="middle"  rowspan="2"  >Std. Error</th><th align="center" valign="middle"  rowspan="2"  >Sig.</th></tr></thead><tr><td align="center" valign="middle" >B</td><td align="center" valign="middle" >Lower Bound</td><td align="center" valign="middle" >Upper Bound</td></tr><tr><td align="center" valign="middle" >Patient age in years</td><td align="center" valign="middle" >0.081</td><td align="center" valign="middle" >0.030</td><td align="center" valign="middle" >0.131</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >Diabetes+</td><td align="center" valign="middle" >2.227</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >3.998</td><td align="center" valign="middle" >0.901</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle" >Hypertension+</td><td align="center" valign="middle" >1.655</td><td align="center" valign="middle" >−0.273</td><td align="center" valign="middle" >3.584</td><td align="center" valign="middle" >0.982</td><td align="center" valign="middle" >0.092</td></tr><tr><td align="center" valign="middle" >Obesity+</td><td align="center" valign="middle" >5.351</td><td align="center" valign="middle" >1.969</td><td align="center" valign="middle" >8.734</td><td align="center" valign="middle" >1.722</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle"  colspan="6"  >Dependent Variable: Duration of inpatient days</td></tr><tr><td align="center" valign="middle"  colspan="6"  >R<sup>2</sup> = 0.101</td></tr></tbody></table></table-wrap></sec><sec id="s3_4"><title>3.4 Cluster Type and Secondary Attack Rates</title><p>A total of 158 clusters containing 2949 contacts were identified from case records and were categorised into 3 groups based on their exposure settings. They were workplace (1273 contacts in 56 clusters), dormitory (780 contacts in 26 clusters) and family-household (896 contacts in 76 clusters). A total of 694 contacts among these clusters (295, 201 and 195 in the workplace, dormitory and family respectively) developed symptoms and were confirmed as Covid-19 cases during their quarantine periods (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>Out of the 694 contacts tested positive, 88 (12.37%) were females and 606 (87.62%) were males (<xref ref-type="table" rid="table4">Table 4</xref>). The median incubation period measured for workplace, dormitory and family groups was 8 days (IQR 4.0 - 15.0), 8 days (IQR 4 - 17) and 4 days (IQR 2.0 - 7.0), respectively. We attempted to analyse the incubation period of contacts who had symptom onset within 14 days from exposure to the index case to further explore the possibility of significant difference between the three groups taking into consideration the higher possibility of heterogeneity in exposures in workplaces and dormitories. Non-parametric comparison (Mann- Whitney U test) revealed no significant difference in the median incubation period between workplace and dormitory contacts, who developed clinical signs and symptoms of COVID-19 within 14 days. However, a significant difference was found between family vs workplace (p = 0.0001) and family vs dormitory groups (p = 0.002) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>The secondary attack rate (SAR) estimated was highest in dormitory clusters 52% (95% CI: 0.40 - 0.63) followed by workplace clusters 41.6% (95% CI: 0.34 - 0.48), and family clusters 33% (95% CI: 0.27 - 0.38). A statistically significant difference was noted in the SAR among the 3 groups (One-Way ANOVA, F (2) = 5.43, p &lt; 0.01).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>The pandemic of COVID-19 constitutes a challenge to global public health security. It is the sixth (PHEIC) since the International Health Regulations (IHR)</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Epidemiological profile of clusters</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Characteristic</th><th align="center" valign="middle" >Workplace</th><th align="center" valign="middle" >Dormitory</th><th align="center" valign="middle" >Family</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Number of clusters</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >76</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Number of listed contacts</td><td align="center" valign="middle" >1273</td><td align="center" valign="middle" >780</td><td align="center" valign="middle" >896</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >Age group</td><td align="center" valign="middle" >0 - 5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >13 (6.56)</td></tr><tr><td align="center" valign="middle" >5 - 13</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >23 (11.61)</td></tr><tr><td align="center" valign="middle" >13 - 21</td><td align="center" valign="middle" >4 (1.36)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >29 (14.64)</td></tr><tr><td align="center" valign="middle" >21 - 45</td><td align="center" valign="middle" >253 (85.76)</td><td align="center" valign="middle" >165 (82.08)</td><td align="center" valign="middle" >109 (55.05)</td></tr><tr><td align="center" valign="middle" >46 - 60</td><td align="center" valign="middle" >36 (12.20)</td><td align="center" valign="middle" >32 (15.92)</td><td align="center" valign="middle" >11 (5.55)</td></tr><tr><td align="center" valign="middle" >60 - 80</td><td align="center" valign="middle" >2 (0.68)</td><td align="center" valign="middle" >4 (1.99)</td><td align="center" valign="middle" >12 (6.06)</td></tr><tr><td align="center" valign="middle" >80 - 100</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (0.50)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Gender</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >1 (0.33)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >87 (43.93)</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >294 (99.66)</td><td align="center" valign="middle" >201</td><td align="center" valign="middle" >111 (56.06)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Number tested positive among contacts</td><td align="center" valign="middle" >295/1273 (23.17%)</td><td align="center" valign="middle" >201/780 (25.76%)</td><td align="center" valign="middle" >198/896 (22.09%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Incubation period Median (IQR )</td><td align="center" valign="middle" >8 (IQR 4.00 - 15.00)</td><td align="center" valign="middle" >8 (IQR 4.00 - 17.00)</td><td align="center" valign="middle" >4 (IQR 2.00 - 7.00)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Among contacts tested positive number within 14 days of exposure.</td><td align="center" valign="middle" >213/295 (72.20)</td><td align="center" valign="middle" >128/201 (63.68)</td><td align="center" valign="middle" >183/198 (92.42)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Secondary attack rate, (Mean, 95% CI)</td><td align="center" valign="middle" >41.60 (95% CI: 0.34 - 0.48)</td><td align="center" valign="middle" >52.00 (95% CI: 0.40 - 0.63)</td><td align="center" valign="middle" >33.19 (95% CI: 0.27 - 0.38)</td></tr></tbody></table></table-wrap><p>**Other comorbidities reported Cancer (N = 5, 0.04%), chronic kidney disease (N = 18, 0.2%), Dyslipidaemia (N = 21, 0.2%), hypothyroidism (N = 9, 0.1%) and systemic lupus erythematosus (SLE) (N = 2, 0.02%).</p><p>2005 has entered into force on 15th June 2007 [<xref ref-type="bibr" rid="scirp.107039-ref17">17</xref>]. According to the IHR, countries should develop their national capacities to prevent, protect against, control and provide public health response to the international spread of diseases and other public health events [<xref ref-type="bibr" rid="scirp.107039-ref18">18</xref>]. However, the implementation phase remains a challenge and countries varied widely in their national core capacities to prevent, detect and control the outbreak, with 28% (52/182) countries had low capacity to prevent public health events and 44 (24%) of countries lacked robust detection capacity. Response capacity to public health events was low in 60 (33%) of countries [<xref ref-type="bibr" rid="scirp.107039-ref19">19</xref>].</p><p>The first imported COVID-19 case was reported on 24th February 2020 followed by a steady but slow increase in travel-associated cases. By mid-March, the dynamics of transmission has gradually shifted from imported cases to local transmission.</p><p>Various strategic interventions were implemented in Muscat to reduce and flatten the peak of impact. It included the closure of schools and academic institutes, shops and limiting the number of employees in various institutes to 30% and a lockdown of some districts.</p><p>The study showed a higher rate of disease among expatriate in the initial phase, however later it affected the Omani population in similar rates. It is to be noted that nearly 64% of the population in Muscat are expatriates. Most of the expatriates are young and blue-collar workers who live in high-density dormitories [<xref ref-type="bibr" rid="scirp.107039-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref20">20</xref>]. This demographic characteristic may explain the distribution of case and males to females’ ratio of (6:1). Similarly, the most affected age group was 21 - 40 years, which is driven by the working-age group and it is consistent with other published data.</p><p>The median incubation period in our study was 4 - 7 days, which is consistent with other reports from various countries [<xref ref-type="bibr" rid="scirp.107039-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref23">23</xref>]. The main types of clusters identified were family, dormitory and workplace clusters. Initially, the transmission was driven by the dormitory clusters, due to expatriate demography mentioned above, soon followed by workplace clusters. The numbers of family clusters increased with disease transmission getting established among Omani population. The increased incubation period found in dormitories and workplace clusters could be attributed to the larger number of exposed contacts and also due to multiple exposures other than the primary case as it was difficult to segregate workers of each room as they were sharing common amenities. The median incubation period from the family cluster is thus a more valid estimate in our context.</p><p>The overall Clinical presentations of most cases were mild to moderate compatible with previously published data [<xref ref-type="bibr" rid="scirp.107039-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref25">25</xref>]. It was noted that the median duration of illness was 5 days for Omanis and 3 days for non-Omanis. Similarly, cough and fever were the main symptoms among the patients included in the study [<xref ref-type="bibr" rid="scirp.107039-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref27">27</xref>]. We noticed at the initial period that patients presented with mild symptoms like rhinitis and headache also reported diarrhoea, anosmia and dysgeusia. Therefore, these symptoms were added later to the case definition.</p><p>The Secondary Attack Rate (SAR) for household contact was 33% in our study, similar to other published data [<xref ref-type="bibr" rid="scirp.107039-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref30">30</xref>]. We also noted that SAR was higher for workplaces and dormitories (41.6% and 52% respectively). This again is indirectly a reflection of the population dynamics in middle east countries and Oman is no exception. 75% of the study population were expatriate (most affected in the first 3 months of the pandemic in Muscat), and they cluster together in workplaces and stays in shared dormitories. Besides that, many workers in the large-sized dormitories were sent for screening regardless of their symptoms. Thus, some of the cases in our analysis were asymptomatic. In our dataset, among the clusters, we encountered certain contacts, who developed symptoms 14 days after the exposure to the primary cases. These findings were indicative of the asymptomatic/pre-symptomatic transmission that could have played a major role in dormitory transmission.</p><p>Although more than 80% of the hospitalized cases were males, the hospital admission rate was slightly higher among females than males. This was analyzed further by nationality and results were consistent between Omanis and expatriate. This difference could be attributed to health-seeking behaviours and less testing among the female population. Admission rates were also higher among older than younger age groups, alcoholics and obese. There was no significant difference in the rates of admission among smokers than non-smokers. There was no gender nor nationality difference between mean days of hospital admission. Age was positively correlated with the duration of hospital admission.</p><p>The majority of patients in our study had good outcomes. However, during pandemics and widespread community transmission, looking at the duration of hospital stay for the admitted patient is critical for planning and predicting countries bed capacity needs. Data on the length of stay (LOS) of patients with COVID-19 in hospital and ICU ranged from 5 days to more than 30 days [<xref ref-type="bibr" rid="scirp.107039-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref34">34</xref>]. From our data, the (LOS) was 9 days, the median hospital stay was 7 days (IQR 1 - 60), median ICU admission was 10 days (IQR 1 - 62) and the median of ventilation was 10 days (IQR 2 - 53).</p><p>COVID-19 mortality rate varied across the globe, ranging from less than 0.1% to over 25% [<xref ref-type="bibr" rid="scirp.107039-ref35">35</xref>]. The CFR for our study was 0.9%, a similar rate was reported by GCC countries. However, mortality varies considerably depending on age, socioeconomic status and underlying health conditions. Furthermore, asymptomatic disease prevalence, changes in the case definition and availability and access to testing could lead to an underestimate of infection rate and mortality [<xref ref-type="bibr" rid="scirp.107039-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.107039-ref37">37</xref>].</p><p>Our study has some limitations. The numbers could be an underestimate since a substantial proportion of the population can either be asymptomatic or have mild symptoms for which they do not approach healthcare facility. Language barriers did exist for ascertaining exposure and contact tracing as most cases were expatriates. To overcome this challenge, we did employ contact tracers from various nationalities to address this issue with varying degrees of success.</p><p>In conclusion, SARS-CoV-2 is a new virus and understanding the epidemiological characteristics of the affected cases will assist the policymakers to understand patterns of epidemiological spread and thus plan for robust interventions.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We would like to thank all head of hospital, heads of health center and private clinic. We thank all focal points in the surveillance team in the Muscat region along with all first line health providers for their dedication and sacrifices.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Al Balushi, L., Al Fahdi, F., Al Ghafri, T., Amin, M., Singh, J., Al Siyabi, B., Al Kalbani, M., Al Kindi, M., Al Balushi, F., Al Ghazaili, H., Al Alwai, M., Al Mashari, S., Al Kindi, H., Al Rumhi, A., Al Shidhani, I., Al Balushi, Z., Kurup, P.J. and Al Ajmi, F. (2021) Epidemiological Characteristics of COVID-19 Confirmed Cases in Muscat Governorate, Sultanate of Oman. Open Journal of Epidemiology, 11, 56-69. https://doi.org/10.4236/ojepi.2021.111006</p></sec></body><back><ref-list><title>References</title><ref id="scirp.107039-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Baud, D., Qi, X., Nielsen-Saines, K., Musso, D., Pomar, L. and Favre, G. (2020) Real Estimates of Mortality Following COVID-19 Infection. The Lancet Infectious Diseases, 20, 773. https://doi.org/10.1016/S1473-3099(20)30195-X</mixed-citation></ref><ref id="scirp.107039-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., et al. (2020) Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis. The Lancet Infectious Diseases, 20, 669-667.  
https://doi.org/10.1016/S1473-3099(20)30243-7</mixed-citation></ref><ref id="scirp.107039-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Estimating Mortality from COVID-19.  
https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19</mixed-citation></ref><ref id="scirp.107039-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rees, E.M., Nightingale, E.S., Jafari, Y., Waterlow, N.R., Clifford, S., Pearson, C.A., et al. (2020) COVID-19 Length of Hospital Stay: A Systematic Review and Data Synthesis. BMC Medicine, 18, Article No. 270.  
https://doi.org/10.1186/s12916-020-01726-3</mixed-citation></ref><ref id="scirp.107039-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lewnard, J.A., Liu, V.X., Jackson, M.L., Schmidt, M.A., Jewell, B.L., Flores, J.P., et al. (2020) Incidence, Clinical Outcomes, and Transmission Dynamics of Severe Coronavirus Disease 2019 in California and Washington: Prospective Cohort Study. BMJ, 369, m1923. https://doi.org/10.1136/bmj.m1923</mixed-citation></ref><ref id="scirp.107039-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Karagiannidis, C., Mostert, C., Hentschker, C., Voshaar, T., Malzahn, J., Schillinger, G., et al. (2020) Case Characteristics, Resource Use, and Outcomes of 10021 Patients with COVID-19 Admitted to 920 German Hospitals: An Observational Study. The Lancet Respiratory Medicine, 8, 853-862.  
https://doi.org/10.1016/S2213-2600(20)30316-7</mixed-citation></ref><ref id="scirp.107039-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bhatraju, P.K., Ghassemieh, B.J., Nichols, M., Kim, R., Jerome, K.R., Nalla, A.K., et al. (2020) Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. New England Journal of Medicine, 382, 2012-2022. 
https://doi.org/10.1056/NEJMoa2004500</mixed-citation></ref><ref id="scirp.107039-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shah, K., Saxena, D. and Mavalankar, D. (2020) Secondary Attack Rate of COVID-19 in Household Contacts: Systematic Review. QJM, 113, 841-850.  
https://doi.org/10.1093/qjmed/hcaa232</mixed-citation></ref><ref id="scirp.107039-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname><given-names> W. W.</given-names></name>,<name name-style="western"><surname> Ling</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Pan</surname><given-names> J. R.</given-names></name>,<name name-style="western"><surname> Cai</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Miao</surname><given-names> Z. P.</given-names></name>,<name name-style="western"><surname> Liu</surname><given-names> S. L.</given-names></name>,<name name-style="western"><surname> et al</surname><given-names> </given-names></name>,<etal>et al</etal>. (<year>2020</year>)<article-title>Epidemiological Characteristics of 2019 Novel Coronavirus Family Clustering in Zhejiang Province</article-title><source> Chinese Journal of Preventive Medicine</source><volume> 54</volume>,<fpage> E027</fpage>-<lpage>E027</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.107039-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Eggo, R.M. and Kucharski, A.J. (2020) Secondary Attack Rate and Superspreading Events for SARS-CoV-2. The Lancet, 395, e47. 
https://doi.org/10.1016/S0140-6736(20)30462-1</mixed-citation></ref><ref id="scirp.107039-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Khalili, M., Karamouzian, M., Nasiri, N., Javadi, S., Mirzazadeh, A. and Sharifi, H. (2020) Epidemiological Characteristics of COVID-19: A Systemic Review and Meta-Analysis. Epidemiology and Infection, 148, e130. 
http://dx.doi.org/10.1017/S0950268820001430</mixed-citation></ref><ref id="scirp.107039-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ji, W., Zhang, J., Bishnu, G., Du, X., Chen, X., Xu, H., et al. (2020) Comparison of Severe and Non-Severe COVID-19 Pneumonia: Review and Meta-Analysis.  
https://doi.org/10.1101/2020.03.04.20030965  
https://www.medrxiv.org/content/10.1101/2020.03.04.20030965v1</mixed-citation></ref><ref id="scirp.107039-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bi, Q.F., Wu, Y.S., Mei, S.J., Ye, C.F., Zou, X., Zhang, Z., et al. (2020) Epidemiology and Transmission of COVID-19 in 391 Cases and 1286 of Their Close Contacts in Shenzhen, China: A Retrospective Cohort Study. The Lancet Infectious Diseases, 20, 911-919. https://doi.org/10.1016/S1473-3099(20)30287-5</mixed-citation></ref><ref id="scirp.107039-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020) The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China. Chinese Journal of Epidemiology, 41, 145-151.  
https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003</mixed-citation></ref><ref id="scirp.107039-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y. and Liu, Q. (2020) The Epidemic Dynamics of 2019 Novel Coronavirus (2019-nCoV) Infections in China by 28 January. SSRN Electronic Journal.  
https://doi.org/10.2139/ssrn.3529448</mixed-citation></ref><ref id="scirp.107039-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wu, W., Li, Y., Wei, Z., Zhou, P., Lyu, L., Zhang, G., Zhao, Y., He, H., Li, X., Gao, L., Zhang, X., Liu, H., Zhou, N., Guo, Y., Zhang, X., Zhang, D., Liu, J. and Zhang, Y. (2020) Investigation and Analysis of the Clustered Epidemic Situation of Novel Coronavirus Pneumonia in a Department Store in Tianjin. Chinese Journal of Epidemiology, 41, Epub Ahead of Print.</mixed-citation></ref><ref id="scirp.107039-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Backer, J.A., Klinkenberg, D. and Wallinga, J. (2020) Incubation Period of 2019 Novel Coronavirus (2019-nCoV) Infections among Travellers from Wuhan, China, 20-28 January 2020. Eurosurveillance, 25.  
https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062</mixed-citation></ref><ref id="scirp.107039-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Khamis, F., Al Rashidi, B., Al-Zakwani, I., Al Wahaibi, A. and Al Awaidy, S. (2020) Epidemiology of COVID-19 Infection in Oman: Analysis of the First 1304 Cases. Oman Medical Journal, 35, e145. https://doi.org/10.5001/omj.2020.60</mixed-citation></ref><ref id="scirp.107039-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kandel, N., Chungong, S., Omaar, A. and Xing, J. (2020) Health Security Capacities in the Context of COVID-19 Outbreak: An Analysis of International Health Regulations Annual Report Data from 182 Countries. The Lancet, 395, 1047-1053. 
https://doi.org/10.1016/S0140-6736(20)30553-5</mixed-citation></ref><ref id="scirp.107039-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2008) International Health Regulations (2005) World Health Organization.</mixed-citation></ref><ref id="scirp.107039-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mullen, L., Potter, C., Gostin, L.O., Cicero, A. and Nuzzo, J.B. (2020) An Analysis of International Health Regulations Emergency Committees and Public Health Emergency of International Concern Designations. BMJ Global Health, 5, Article ID: e002502.  
https://doi.org/10.1136/bmjgh-2020-002502</mixed-citation></ref><ref id="scirp.107039-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Civil Aviation Authority (n.d.) Homepage. https://www.paca.gov.om/</mixed-citation></ref><ref id="scirp.107039-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">National Center for Statistics and Information (2020) Population Data Portal.  
https://data.gov.om/OMPOP2016/population</mixed-citation></ref><ref id="scirp.107039-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ministry of Health (2020) COVID-19 Algorithm for Primary Health, Non-MOH and Private Health Institutes. 
https://www.moh.gov.om/documents/10194/3832510/COVID-19</mixed-citation></ref><ref id="scirp.107039-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Laboratory Testing for 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases.  
https://www.who.int/publications/i/item/10665-331501</mixed-citation></ref><ref id="scirp.107039-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., et al. (2020) Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR. European Communicable Disease Bulletin, 25, 2000045. 
https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045</mixed-citation></ref><ref id="scirp.107039-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ministry of Health (2020) Ministry of Health Statement No. 31.  
https://www.moh.gov.om/en/-/--1294</mixed-citation></ref><ref id="scirp.107039-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ministry of Health (2020) Ministry of Health Statement No. 29.  
https://www.moh.gov.om/en/-/-29-26-2020-10-</mixed-citation></ref><ref id="scirp.107039-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Koh, G. (2020) Faculty Opinions Recommendation of Report of the World Health Organization-China Joint Mission on Coronavirus Disease 2019 (COVID-19).  
https://doi.org/10.3410/f.737509210.793572110</mixed-citation></ref><ref id="scirp.107039-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.  
https://doi.org/10.1001/jama.2020.1585</mixed-citation></ref><ref id="scirp.107039-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Cascella, M., Rajnik, M, Cuomo, A., Dulebohn, S.C. and Di Napoli, R. (2020) Features, Evaluation, and Treatment of Coronavirus (COVID-19).  
https://www.ncbi.nlm.nih.gov/books/NBK554776</mixed-citation></ref><ref id="scirp.107039-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Petersen, E., Koopmans, M., Go, U., Hamer, D.H., Petrosillo, N., Castelli, F., et al. (2020) Comparing SARS-CoV-2 with SARS-CoV and Influenza Pandemics. The Lancet Infectious Diseases, 20, E238-E244. 
https://doi.org/10.1016/S1473-3099(20)30484-9</mixed-citation></ref><ref id="scirp.107039-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Remuzzi, A. and Remuzzi, G. (2020) COVID-19 and Italy: What Next? Lancet, 395 1225-1228. https://doi.org/10.1016/S0140-6736(20)30627-9</mixed-citation></ref><ref id="scirp.107039-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Coronavirus Disease (COVID-19) Situation Report-132.  
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200531-covid-19-sitrep-132.pdf?sfvrsn=d9c2eaef_2</mixed-citation></ref><ref id="scirp.107039-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="scirp.107039-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV).  
https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)</mixed-citation></ref><ref id="scirp.107039-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032</mixed-citation></ref></ref-list></back></article>